Costamare Inc. (NYSE:CMRE) appreciated by 2.56% at $6.41, after hitting low of $6.18 in an intra-day trade. Costamare Inc. has 104.32 million shares outstanding, and in the last trade has seen ATR around 0.25. The volume of CMRE witnessed a down move from 1.02 million shares, based on a 50-day average, to 705.14 thousand shares.
In the most updated research from a number of analysts on Wall Street, the company gets 3 Buys and 0 Sell among 7 analysts. Costamare Inc. (NYSE:CMRE) recently traded as high as $6.51. The consensus analyst target price is $8.67. That gives us a street projected return of 35.26. If the published price targets set by Costamare Inc. analysts have any power to influence the stock’s share price, the highest price target set for CMRE is $10.
Costamare Inc. most recently reported earnings per share (EPS) of $0.21 for the 3 months ending 2017-06-30 versus $0.42 in the same quarter last year, representing -50% growth. Analysts had predicted $0.2.Revenue during the quarter was $105.02 million, representing -12% growth from $119.53 million in year-ago quarter. The company’s quarterly EPS surprised Wall Street by as much as 5% to the upside in its last earnings announcement, so investors should note this tendency when assessing consensus estimates.
On a similar note, analysts expect EPS of $0.19 in September 2017 quarter and $0.18 in December 2017 quarter, representing -48.65% and -36.43% growth, respectively. They expect this year’s earnings to rise 0.83% year-over-year to -$44.3, followed by -13.49% decline in the next year to $0.72.
Shares of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) traded up 1.68% in the last session while performance was up 6.05% in the last five days. The stock’s last price was lower from the average trading price of 50 days recorded at $6.72 while enlarging the period to 200 trading days, the average price was $6.51. Currently, 50.78 million total shares are owned by the public and among those 50.78 million shares have been available to trade. The percentage of shares being held by the company management was 0.1% while institutional stake was 43%.
Tetraphase Pharmaceuticals, Inc. (TTPH) is recuperating from the fall at $3.11, the 52-week low. The stock has risen 94.53% since then. The trading saw a strength at $9.93, the 52-week high. But since then, those gains have faded by -39.07%. CMRE has lost -12.32% in the 1-month period.
Costamare Inc. has a beta of 2.21, offering the possibility of a higher rate of return, but also posing more risk. The portion of a company’s profit allocated to each outstanding share of common stock was -$2.81 a share in the trailing twelve months. It last reported revenues of $1.59 million and EPS of -$0.83 for the 3 months ending 2017-06-30, representing 28% top-line growth and -0.47 EPS growth.
Looking forward, the company’s quarterly earnings are expected to come at -$0.58 in the three months through September 2017 and -$0.47 in the quarter ending December, reflecting 0.57% and 23.5% growth, respectively. For the full year, analysts expect earnings to decline -2.55% yoy to -$20.85. Next year this growth will reach 27.55% to attain -$1.85.